nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—Fluid overload—Carboplatin—esophageal cancer	0.0485	0.0523	CcSEcCtD
Salbutamol—Autonomic neuropathy—Cisplatin—esophageal cancer	0.039	0.042	CcSEcCtD
Salbutamol—Hoarseness—Capecitabine—esophageal cancer	0.0148	0.016	CcSEcCtD
Salbutamol—Fluid overload—Cisplatin—esophageal cancer	0.0142	0.0153	CcSEcCtD
Salbutamol—Infection—Carboplatin—esophageal cancer	0.0107	0.0115	CcSEcCtD
Salbutamol—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.00996	0.0107	CcSEcCtD
Salbutamol—Appetite absent—Methotrexate—esophageal cancer	0.00976	0.0105	CcSEcCtD
Salbutamol—Ileus—Capecitabine—esophageal cancer	0.00922	0.00993	CcSEcCtD
Salbutamol—Pain—Carboplatin—esophageal cancer	0.00921	0.00992	CcSEcCtD
Salbutamol—Laryngitis—Capecitabine—esophageal cancer	0.00905	0.00975	CcSEcCtD
Salbutamol—Wheezing—Cisplatin—esophageal cancer	0.0086	0.00926	CcSEcCtD
Salbutamol—Body temperature increased—Carboplatin—esophageal cancer	0.00851	0.00917	CcSEcCtD
Salbutamol—Coagulopathy—Capecitabine—esophageal cancer	0.00838	0.00903	CcSEcCtD
Salbutamol—Otitis media—Capecitabine—esophageal cancer	0.00838	0.00903	CcSEcCtD
Salbutamol—Hyperaesthesia—Capecitabine—esophageal cancer	0.00831	0.00896	CcSEcCtD
Salbutamol—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00812	0.00874	CcSEcCtD
Salbutamol—Rigors—Capecitabine—esophageal cancer	0.00799	0.00861	CcSEcCtD
Salbutamol—Dysphonia—Capecitabine—esophageal cancer	0.00793	0.00854	CcSEcCtD
Salbutamol—Extrasystoles—Capecitabine—esophageal cancer	0.00775	0.00835	CcSEcCtD
Salbutamol—Chest discomfort—Capecitabine—esophageal cancer	0.00737	0.00794	CcSEcCtD
Salbutamol—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.00722	0.00778	CcSEcCtD
Salbutamol—Herpes simplex—Capecitabine—esophageal cancer	0.00708	0.00763	CcSEcCtD
Salbutamol—Nasal congestion—Cisplatin—esophageal cancer	0.00705	0.0076	CcSEcCtD
Salbutamol—Lung disorder—Methotrexate—esophageal cancer	0.00686	0.00739	CcSEcCtD
Salbutamol—Inflammation—Capecitabine—esophageal cancer	0.00673	0.00725	CcSEcCtD
Salbutamol—Blood pressure increased—Capecitabine—esophageal cancer	0.00653	0.00703	CcSEcCtD
Salbutamol—Irritability—Cisplatin—esophageal cancer	0.00613	0.00661	CcSEcCtD
Salbutamol—Hypokalaemia—Cisplatin—esophageal cancer	0.00585	0.0063	CcSEcCtD
Salbutamol—Cramp muscle—Cisplatin—esophageal cancer	0.00579	0.00623	CcSEcCtD
Salbutamol—Nasopharyngitis—Cisplatin—esophageal cancer	0.00575	0.00619	CcSEcCtD
Salbutamol—Mental disability—Capecitabine—esophageal cancer	0.00566	0.0061	CcSEcCtD
Salbutamol—Ear pain—Capecitabine—esophageal cancer	0.00555	0.00598	CcSEcCtD
Salbutamol—Diabetes mellitus—Capecitabine—esophageal cancer	0.00545	0.00587	CcSEcCtD
Salbutamol—Sweating increased—Cisplatin—esophageal cancer	0.00541	0.00583	CcSEcCtD
Salbutamol—Gastroenteritis—Capecitabine—esophageal cancer	0.00534	0.00576	CcSEcCtD
Salbutamol—Herpes simplex—Methotrexate—esophageal cancer	0.00527	0.00568	CcSEcCtD
Salbutamol—Glossitis—Methotrexate—esophageal cancer	0.00527	0.00568	CcSEcCtD
Salbutamol—Increased appetite—Capecitabine—esophageal cancer	0.00504	0.00543	CcSEcCtD
Salbutamol—Inflammation—Methotrexate—esophageal cancer	0.00501	0.00539	CcSEcCtD
Salbutamol—Atrial fibrillation—Capecitabine—esophageal cancer	0.005	0.00538	CcSEcCtD
Salbutamol—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00485	0.00523	CcSEcCtD
Salbutamol—Stomatitis—Cisplatin—esophageal cancer	0.00483	0.0052	CcSEcCtD
Salbutamol—Conjunctivitis—Cisplatin—esophageal cancer	0.00481	0.00519	CcSEcCtD
Salbutamol—Migraine—Capecitabine—esophageal cancer	0.00466	0.00502	CcSEcCtD
Salbutamol—Irritability—Capecitabine—esophageal cancer	0.00452	0.00487	CcSEcCtD
Salbutamol—Mood swings—Capecitabine—esophageal cancer	0.00449	0.00483	CcSEcCtD
Salbutamol—Ataxia—Capecitabine—esophageal cancer	0.00445	0.0048	CcSEcCtD
Salbutamol—Urinary tract disorder—Cisplatin—esophageal cancer	0.00439	0.00473	CcSEcCtD
Salbutamol—Connective tissue disorder—Cisplatin—esophageal cancer	0.00437	0.00471	CcSEcCtD
Salbutamol—Urethral disorder—Cisplatin—esophageal cancer	0.00436	0.00469	CcSEcCtD
Salbutamol—Abdominal pain upper—Capecitabine—esophageal cancer	0.00433	0.00466	CcSEcCtD
Salbutamol—Pulmonary oedema—Methotrexate—esophageal cancer	0.00432	0.00466	CcSEcCtD
Salbutamol—Hypokalaemia—Capecitabine—esophageal cancer	0.00431	0.00464	CcSEcCtD
Salbutamol—Nasopharyngitis—Capecitabine—esophageal cancer	0.00424	0.00456	CcSEcCtD
Salbutamol—Tinnitus—Cisplatin—esophageal cancer	0.00414	0.00446	CcSEcCtD
Salbutamol—Lymphadenopathy—Methotrexate—esophageal cancer	0.00413	0.00445	CcSEcCtD
Salbutamol—Cardiac disorder—Cisplatin—esophageal cancer	0.00413	0.00444	CcSEcCtD
Salbutamol—Flushing—Cisplatin—esophageal cancer	0.00413	0.00444	CcSEcCtD
Salbutamol—Abdominal distension—Capecitabine—esophageal cancer	0.00412	0.00444	CcSEcCtD
Salbutamol—Asthma—Capecitabine—esophageal cancer	0.00409	0.00441	CcSEcCtD
Salbutamol—Influenza—Capecitabine—esophageal cancer	0.00409	0.00441	CcSEcCtD
Salbutamol—Diabetes mellitus—Methotrexate—esophageal cancer	0.00405	0.00437	CcSEcCtD
Salbutamol—Bronchospasm—Capecitabine—esophageal cancer	0.00403	0.00434	CcSEcCtD
Salbutamol—Immune system disorder—Cisplatin—esophageal cancer	0.00402	0.00433	CcSEcCtD
Salbutamol—Mediastinal disorder—Cisplatin—esophageal cancer	0.00401	0.00432	CcSEcCtD
Salbutamol—Angina pectoris—Capecitabine—esophageal cancer	0.00399	0.0043	CcSEcCtD
Salbutamol—Sweating increased—Capecitabine—esophageal cancer	0.00399	0.0043	CcSEcCtD
Salbutamol—Arrhythmia—Cisplatin—esophageal cancer	0.00397	0.00428	CcSEcCtD
Salbutamol—Bronchitis—Capecitabine—esophageal cancer	0.00394	0.00424	CcSEcCtD
Salbutamol—Malnutrition—Cisplatin—esophageal cancer	0.00387	0.00417	CcSEcCtD
Salbutamol—Dysuria—Capecitabine—esophageal cancer	0.00383	0.00412	CcSEcCtD
Salbutamol—Flatulence—Cisplatin—esophageal cancer	0.00381	0.00411	CcSEcCtD
Salbutamol—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.0038	0.0041	CcSEcCtD
Salbutamol—Muscle spasms—Cisplatin—esophageal cancer	0.00372	0.00401	CcSEcCtD
Salbutamol—Hyperglycaemia—Capecitabine—esophageal cancer	0.00369	0.00398	CcSEcCtD
Salbutamol—Tremor—Cisplatin—esophageal cancer	0.00363	0.00391	CcSEcCtD
Salbutamol—Ill-defined disorder—Cisplatin—esophageal cancer	0.00359	0.00387	CcSEcCtD
Salbutamol—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00358	0.00385	CcSEcCtD
Salbutamol—Jaundice—Capecitabine—esophageal cancer	0.00356	0.00383	CcSEcCtD
Salbutamol—Stomatitis—Capecitabine—esophageal cancer	0.00356	0.00383	CcSEcCtD
Salbutamol—Conjunctivitis—Capecitabine—esophageal cancer	0.00355	0.00382	CcSEcCtD
Salbutamol—Urinary tract infection—Capecitabine—esophageal cancer	0.00355	0.00382	CcSEcCtD
Salbutamol—Malaise—Cisplatin—esophageal cancer	0.00349	0.00376	CcSEcCtD
Salbutamol—Haematuria—Capecitabine—esophageal cancer	0.00348	0.00375	CcSEcCtD
Salbutamol—Epistaxis—Capecitabine—esophageal cancer	0.00344	0.00371	CcSEcCtD
Salbutamol—Irritability—Methotrexate—esophageal cancer	0.00337	0.00363	CcSEcCtD
Salbutamol—Mood swings—Methotrexate—esophageal cancer	0.00334	0.0036	CcSEcCtD
Salbutamol—Ataxia—Methotrexate—esophageal cancer	0.00332	0.00357	CcSEcCtD
Salbutamol—Myalgia—Cisplatin—esophageal cancer	0.00329	0.00355	CcSEcCtD
Salbutamol—Haemoglobin—Capecitabine—esophageal cancer	0.00329	0.00355	CcSEcCtD
Salbutamol—Rhinitis—Capecitabine—esophageal cancer	0.00329	0.00354	CcSEcCtD
Salbutamol—Anxiety—Cisplatin—esophageal cancer	0.00328	0.00354	CcSEcCtD
Salbutamol—Haemorrhage—Capecitabine—esophageal cancer	0.00328	0.00353	CcSEcCtD
Salbutamol—Hypoaesthesia—Capecitabine—esophageal cancer	0.00326	0.00351	CcSEcCtD
Salbutamol—Discomfort—Cisplatin—esophageal cancer	0.00326	0.00351	CcSEcCtD
Salbutamol—Pharyngitis—Capecitabine—esophageal cancer	0.00325	0.0035	CcSEcCtD
Salbutamol—Urinary tract disorder—Capecitabine—esophageal cancer	0.00324	0.00349	CcSEcCtD
Salbutamol—Connective tissue disorder—Capecitabine—esophageal cancer	0.00322	0.00347	CcSEcCtD
Salbutamol—Urethral disorder—Capecitabine—esophageal cancer	0.00321	0.00346	CcSEcCtD
Salbutamol—Anaphylactic shock—Cisplatin—esophageal cancer	0.00316	0.0034	CcSEcCtD
Salbutamol—Oedema—Cisplatin—esophageal cancer	0.00316	0.0034	CcSEcCtD
Salbutamol—Infection—Cisplatin—esophageal cancer	0.00314	0.00338	CcSEcCtD
Salbutamol—Nervous system disorder—Cisplatin—esophageal cancer	0.0031	0.00334	CcSEcCtD
Salbutamol—Tachycardia—Cisplatin—esophageal cancer	0.00308	0.00332	CcSEcCtD
Salbutamol—Skin disorder—Cisplatin—esophageal cancer	0.00307	0.0033	CcSEcCtD
Salbutamol—Tinnitus—Capecitabine—esophageal cancer	0.00306	0.00329	CcSEcCtD
Salbutamol—Hyperhidrosis—Cisplatin—esophageal cancer	0.00305	0.00329	CcSEcCtD
Salbutamol—Asthma—Methotrexate—esophageal cancer	0.00305	0.00328	CcSEcCtD
Salbutamol—Cardiac disorder—Capecitabine—esophageal cancer	0.00304	0.00328	CcSEcCtD
Salbutamol—Flushing—Capecitabine—esophageal cancer	0.00304	0.00328	CcSEcCtD
Salbutamol—Anorexia—Cisplatin—esophageal cancer	0.00301	0.00324	CcSEcCtD
Salbutamol—Angiopathy—Capecitabine—esophageal cancer	0.00297	0.0032	CcSEcCtD
Salbutamol—Immune system disorder—Capecitabine—esophageal cancer	0.00296	0.00319	CcSEcCtD
Salbutamol—Mediastinal disorder—Capecitabine—esophageal cancer	0.00295	0.00318	CcSEcCtD
Salbutamol—Hypotension—Cisplatin—esophageal cancer	0.00295	0.00318	CcSEcCtD
Salbutamol—Chills—Capecitabine—esophageal cancer	0.00294	0.00317	CcSEcCtD
Salbutamol—Arrhythmia—Capecitabine—esophageal cancer	0.00293	0.00315	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00288	0.0031	CcSEcCtD
Salbutamol—Mental disorder—Capecitabine—esophageal cancer	0.00287	0.00309	CcSEcCtD
Salbutamol—Malnutrition—Capecitabine—esophageal cancer	0.00285	0.00307	CcSEcCtD
Salbutamol—Dysuria—Methotrexate—esophageal cancer	0.00285	0.00307	CcSEcCtD
Salbutamol—Paraesthesia—Cisplatin—esophageal cancer	0.00284	0.00305	CcSEcCtD
Salbutamol—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00283	0.00305	CcSEcCtD
Salbutamol—Dyspnoea—Cisplatin—esophageal cancer	0.00282	0.00303	CcSEcCtD
Salbutamol—Flatulence—Capecitabine—esophageal cancer	0.00281	0.00303	CcSEcCtD
Salbutamol—Dysgeusia—Capecitabine—esophageal cancer	0.00279	0.00301	CcSEcCtD
Salbutamol—Back pain—Capecitabine—esophageal cancer	0.00276	0.00297	CcSEcCtD
Salbutamol—Decreased appetite—Cisplatin—esophageal cancer	0.00275	0.00296	CcSEcCtD
Salbutamol—Muscle spasms—Capecitabine—esophageal cancer	0.00274	0.00295	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00273	0.00294	CcSEcCtD
Salbutamol—Drowsiness—Methotrexate—esophageal cancer	0.00272	0.00293	CcSEcCtD
Salbutamol—Pain—Cisplatin—esophageal cancer	0.0027	0.00291	CcSEcCtD
Salbutamol—Tremor—Capecitabine—esophageal cancer	0.00267	0.00288	CcSEcCtD
Salbutamol—Stomatitis—Methotrexate—esophageal cancer	0.00265	0.00285	CcSEcCtD
Salbutamol—Ill-defined disorder—Capecitabine—esophageal cancer	0.00265	0.00285	CcSEcCtD
Salbutamol—Conjunctivitis—Methotrexate—esophageal cancer	0.00264	0.00285	CcSEcCtD
Salbutamol—Sweating—Methotrexate—esophageal cancer	0.00261	0.00281	CcSEcCtD
Salbutamol—Feeling abnormal—Cisplatin—esophageal cancer	0.0026	0.0028	CcSEcCtD
Salbutamol—Haematuria—Methotrexate—esophageal cancer	0.00259	0.00279	CcSEcCtD
Salbutamol—Malaise—Capecitabine—esophageal cancer	0.00257	0.00277	CcSEcCtD
Salbutamol—Epistaxis—Methotrexate—esophageal cancer	0.00256	0.00276	CcSEcCtD
Salbutamol—Vertigo—Capecitabine—esophageal cancer	0.00256	0.00276	CcSEcCtD
Salbutamol—Syncope—Capecitabine—esophageal cancer	0.00256	0.00276	CcSEcCtD
Salbutamol—Palpitations—Capecitabine—esophageal cancer	0.00252	0.00272	CcSEcCtD
Salbutamol—Loss of consciousness—Capecitabine—esophageal cancer	0.00251	0.0027	CcSEcCtD
Salbutamol—Body temperature increased—Cisplatin—esophageal cancer	0.0025	0.00269	CcSEcCtD
Salbutamol—Cough—Capecitabine—esophageal cancer	0.00249	0.00268	CcSEcCtD
Salbutamol—Hypertension—Capecitabine—esophageal cancer	0.00246	0.00265	CcSEcCtD
Salbutamol—Haemoglobin—Methotrexate—esophageal cancer	0.00245	0.00264	CcSEcCtD
Salbutamol—Haemorrhage—Methotrexate—esophageal cancer	0.00244	0.00263	CcSEcCtD
Salbutamol—Arthralgia—Capecitabine—esophageal cancer	0.00243	0.00262	CcSEcCtD
Salbutamol—Chest pain—Capecitabine—esophageal cancer	0.00243	0.00262	CcSEcCtD
Salbutamol—Myalgia—Capecitabine—esophageal cancer	0.00243	0.00262	CcSEcCtD
Salbutamol—Pharyngitis—Methotrexate—esophageal cancer	0.00242	0.00261	CcSEcCtD
Salbutamol—Anxiety—Capecitabine—esophageal cancer	0.00242	0.00261	CcSEcCtD
Salbutamol—Urinary tract disorder—Methotrexate—esophageal cancer	0.00241	0.0026	CcSEcCtD
Salbutamol—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00241	0.0336	CbGpPWpGaD
Salbutamol—Discomfort—Capecitabine—esophageal cancer	0.0024	0.00258	CcSEcCtD
Salbutamol—Urethral disorder—Methotrexate—esophageal cancer	0.00239	0.00258	CcSEcCtD
Salbutamol—Dry mouth—Capecitabine—esophageal cancer	0.00238	0.00256	CcSEcCtD
Salbutamol—Oedema—Capecitabine—esophageal cancer	0.00233	0.00251	CcSEcCtD
Salbutamol—Hypersensitivity—Cisplatin—esophageal cancer	0.00233	0.00251	CcSEcCtD
Salbutamol—Infection—Capecitabine—esophageal cancer	0.00231	0.00249	CcSEcCtD
Salbutamol—Shock—Capecitabine—esophageal cancer	0.00229	0.00247	CcSEcCtD
Salbutamol—Nervous system disorder—Capecitabine—esophageal cancer	0.00228	0.00246	CcSEcCtD
Salbutamol—Tinnitus—Methotrexate—esophageal cancer	0.00227	0.00245	CcSEcCtD
Salbutamol—Tachycardia—Capecitabine—esophageal cancer	0.00227	0.00245	CcSEcCtD
Salbutamol—Asthenia—Cisplatin—esophageal cancer	0.00227	0.00244	CcSEcCtD
Salbutamol—Cardiac disorder—Methotrexate—esophageal cancer	0.00226	0.00244	CcSEcCtD
Salbutamol—Skin disorder—Capecitabine—esophageal cancer	0.00226	0.00244	CcSEcCtD
Salbutamol—Hyperhidrosis—Capecitabine—esophageal cancer	0.00225	0.00242	CcSEcCtD
Salbutamol—Anorexia—Capecitabine—esophageal cancer	0.00222	0.00239	CcSEcCtD
Salbutamol—Angiopathy—Methotrexate—esophageal cancer	0.00221	0.00238	CcSEcCtD
Salbutamol—Immune system disorder—Methotrexate—esophageal cancer	0.0022	0.00237	CcSEcCtD
Salbutamol—Mediastinal disorder—Methotrexate—esophageal cancer	0.0022	0.00237	CcSEcCtD
Salbutamol—Chills—Methotrexate—esophageal cancer	0.00219	0.00236	CcSEcCtD
Salbutamol—Hypotension—Capecitabine—esophageal cancer	0.00218	0.00234	CcSEcCtD
Salbutamol—Diarrhoea—Cisplatin—esophageal cancer	0.00216	0.00233	CcSEcCtD
Salbutamol—Mental disorder—Methotrexate—esophageal cancer	0.00214	0.0023	CcSEcCtD
Salbutamol—Malnutrition—Methotrexate—esophageal cancer	0.00212	0.00229	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00212	0.00228	CcSEcCtD
Salbutamol—Insomnia—Capecitabine—esophageal cancer	0.00211	0.00227	CcSEcCtD
Salbutamol—Paraesthesia—Capecitabine—esophageal cancer	0.00209	0.00225	CcSEcCtD
Salbutamol—Dysgeusia—Methotrexate—esophageal cancer	0.00208	0.00224	CcSEcCtD
Salbutamol—Dyspnoea—Capecitabine—esophageal cancer	0.00208	0.00224	CcSEcCtD
Salbutamol—Back pain—Methotrexate—esophageal cancer	0.00205	0.00221	CcSEcCtD
Salbutamol—Dyspepsia—Capecitabine—esophageal cancer	0.00205	0.00221	CcSEcCtD
Salbutamol—Decreased appetite—Capecitabine—esophageal cancer	0.00202	0.00218	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00201	0.00217	CcSEcCtD
Salbutamol—Vomiting—Cisplatin—esophageal cancer	0.00201	0.00216	CcSEcCtD
Salbutamol—Fatigue—Capecitabine—esophageal cancer	0.00201	0.00216	CcSEcCtD
Salbutamol—Rash—Cisplatin—esophageal cancer	0.00199	0.00215	CcSEcCtD
Salbutamol—Pain—Capecitabine—esophageal cancer	0.00199	0.00214	CcSEcCtD
Salbutamol—Constipation—Capecitabine—esophageal cancer	0.00199	0.00214	CcSEcCtD
Salbutamol—Dermatitis—Cisplatin—esophageal cancer	0.00199	0.00214	CcSEcCtD
Salbutamol—Ill-defined disorder—Methotrexate—esophageal cancer	0.00197	0.00212	CcSEcCtD
Salbutamol—Feeling abnormal—Capecitabine—esophageal cancer	0.00192	0.00207	CcSEcCtD
Salbutamol—Malaise—Methotrexate—esophageal cancer	0.00191	0.00206	CcSEcCtD
Salbutamol—Vertigo—Methotrexate—esophageal cancer	0.00191	0.00206	CcSEcCtD
Salbutamol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.0019	0.00205	CcSEcCtD
Salbutamol—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.0019	0.0265	CbGpPWpGaD
Salbutamol—Nausea—Cisplatin—esophageal cancer	0.00188	0.00202	CcSEcCtD
Salbutamol—Cough—Methotrexate—esophageal cancer	0.00185	0.002	CcSEcCtD
Salbutamol—Urticaria—Capecitabine—esophageal cancer	0.00185	0.00199	CcSEcCtD
Salbutamol—Abdominal pain—Capecitabine—esophageal cancer	0.00184	0.00198	CcSEcCtD
Salbutamol—Body temperature increased—Capecitabine—esophageal cancer	0.00184	0.00198	CcSEcCtD
Salbutamol—Arthralgia—Methotrexate—esophageal cancer	0.00181	0.00195	CcSEcCtD
Salbutamol—Chest pain—Methotrexate—esophageal cancer	0.00181	0.00195	CcSEcCtD
Salbutamol—Myalgia—Methotrexate—esophageal cancer	0.00181	0.00195	CcSEcCtD
Salbutamol—Discomfort—Methotrexate—esophageal cancer	0.00179	0.00192	CcSEcCtD
Salbutamol—Anaphylactic shock—Methotrexate—esophageal cancer	0.00173	0.00187	CcSEcCtD
Salbutamol—ADRB1—Melatonin metabolism and effects—CYP1B1—esophageal cancer	0.00173	0.0241	CbGpPWpGaD
Salbutamol—Infection—Methotrexate—esophageal cancer	0.00172	0.00185	CcSEcCtD
Salbutamol—Hypersensitivity—Capecitabine—esophageal cancer	0.00172	0.00185	CcSEcCtD
Salbutamol—Nervous system disorder—Methotrexate—esophageal cancer	0.0017	0.00183	CcSEcCtD
Salbutamol—Skin disorder—Methotrexate—esophageal cancer	0.00168	0.00181	CcSEcCtD
Salbutamol—Hyperhidrosis—Methotrexate—esophageal cancer	0.00168	0.0018	CcSEcCtD
Salbutamol—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00167	0.0233	CbGpPWpGaD
Salbutamol—Asthenia—Capecitabine—esophageal cancer	0.00167	0.0018	CcSEcCtD
Salbutamol—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00167	0.0233	CbGpPWpGaD
Salbutamol—Anorexia—Methotrexate—esophageal cancer	0.00165	0.00178	CcSEcCtD
Salbutamol—Pruritus—Capecitabine—esophageal cancer	0.00165	0.00177	CcSEcCtD
Salbutamol—Hypotension—Methotrexate—esophageal cancer	0.00162	0.00174	CcSEcCtD
Salbutamol—Diarrhoea—Capecitabine—esophageal cancer	0.00159	0.00172	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00158	0.0017	CcSEcCtD
Salbutamol—Insomnia—Methotrexate—esophageal cancer	0.00157	0.00169	CcSEcCtD
Salbutamol—Paraesthesia—Methotrexate—esophageal cancer	0.00156	0.00168	CcSEcCtD
Salbutamol—Dyspnoea—Methotrexate—esophageal cancer	0.00155	0.00166	CcSEcCtD
Salbutamol—Somnolence—Methotrexate—esophageal cancer	0.00154	0.00166	CcSEcCtD
Salbutamol—Dizziness—Capecitabine—esophageal cancer	0.00154	0.00166	CcSEcCtD
Salbutamol—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00154	0.0214	CbGpPWpGaD
Salbutamol—Dyspepsia—Methotrexate—esophageal cancer	0.00153	0.00164	CcSEcCtD
Salbutamol—Decreased appetite—Methotrexate—esophageal cancer	0.00151	0.00162	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.0015	0.00161	CcSEcCtD
Salbutamol—Fatigue—Methotrexate—esophageal cancer	0.00149	0.00161	CcSEcCtD
Salbutamol—Pain—Methotrexate—esophageal cancer	0.00148	0.0016	CcSEcCtD
Salbutamol—Vomiting—Capecitabine—esophageal cancer	0.00148	0.00159	CcSEcCtD
Salbutamol—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00148	0.0206	CbGpPWpGaD
Salbutamol—Rash—Capecitabine—esophageal cancer	0.00147	0.00158	CcSEcCtD
Salbutamol—Dermatitis—Capecitabine—esophageal cancer	0.00147	0.00158	CcSEcCtD
Salbutamol—Headache—Capecitabine—esophageal cancer	0.00146	0.00157	CcSEcCtD
Salbutamol—ADRB2—Arf6 trafficking events—CTNNA1—esophageal cancer	0.00143	0.02	CbGpPWpGaD
Salbutamol—Feeling abnormal—Methotrexate—esophageal cancer	0.00143	0.00154	CcSEcCtD
Salbutamol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00142	0.00153	CcSEcCtD
Salbutamol—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00141	0.0197	CbGpPWpGaD
Salbutamol—Nausea—Capecitabine—esophageal cancer	0.00138	0.00149	CcSEcCtD
Salbutamol—Urticaria—Methotrexate—esophageal cancer	0.00138	0.00148	CcSEcCtD
Salbutamol—Body temperature increased—Methotrexate—esophageal cancer	0.00137	0.00148	CcSEcCtD
Salbutamol—Abdominal pain—Methotrexate—esophageal cancer	0.00137	0.00148	CcSEcCtD
Salbutamol—ADRB1—G alpha (s) signalling events—ADCYAP1—esophageal cancer	0.00136	0.0189	CbGpPWpGaD
Salbutamol—ADRB2—G alpha (s) signalling events—ADCYAP1—esophageal cancer	0.00133	0.0185	CbGpPWpGaD
Salbutamol—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00132	0.0184	CbGpPWpGaD
Salbutamol—Hypersensitivity—Methotrexate—esophageal cancer	0.00128	0.00138	CcSEcCtD
Salbutamol—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00128	0.0178	CbGpPWpGaD
Salbutamol—Asthenia—Methotrexate—esophageal cancer	0.00124	0.00134	CcSEcCtD
Salbutamol—Pruritus—Methotrexate—esophageal cancer	0.00123	0.00132	CcSEcCtD
Salbutamol—Diarrhoea—Methotrexate—esophageal cancer	0.00119	0.00128	CcSEcCtD
Salbutamol—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00117	0.0164	CbGpPWpGaD
Salbutamol—Dizziness—Methotrexate—esophageal cancer	0.00115	0.00123	CcSEcCtD
Salbutamol—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.0011	0.0154	CbGpPWpGaD
Salbutamol—Vomiting—Methotrexate—esophageal cancer	0.0011	0.00119	CcSEcCtD
Salbutamol—ADRB1—Calcium Regulation in the Cardiac Cell—ATP1B2—esophageal cancer	0.0011	0.0154	CbGpPWpGaD
Salbutamol—Rash—Methotrexate—esophageal cancer	0.00109	0.00118	CcSEcCtD
Salbutamol—Dermatitis—Methotrexate—esophageal cancer	0.00109	0.00118	CcSEcCtD
Salbutamol—Headache—Methotrexate—esophageal cancer	0.00109	0.00117	CcSEcCtD
Salbutamol—ADRB2—Calcium Regulation in the Cardiac Cell—ATP1B2—esophageal cancer	0.00108	0.015	CbGpPWpGaD
Salbutamol—Nausea—Methotrexate—esophageal cancer	0.00103	0.00111	CcSEcCtD
Salbutamol—ADRB1—Calcium Regulation in the Cardiac Cell—FKBP1A—esophageal cancer	0.00102	0.0142	CbGpPWpGaD
Salbutamol—ADRB2—Calcium Regulation in the Cardiac Cell—FKBP1A—esophageal cancer	0.000997	0.0139	CbGpPWpGaD
Salbutamol—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.000924	0.0129	CbGpPWpGaD
Salbutamol—ADRB2—Arf6 signaling events—MET—esophageal cancer	0.000917	0.0128	CbGpPWpGaD
Salbutamol—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.000889	0.0124	CbGpPWpGaD
Salbutamol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000848	0.0118	CbGpPWpGaD
Salbutamol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000848	0.0118	CbGpPWpGaD
Salbutamol—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00081	0.0113	CbGpPWpGaD
Salbutamol—ADRB1—G alpha (s) signalling events—PDE4D—esophageal cancer	0.0008	0.0112	CbGpPWpGaD
Salbutamol—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000793	0.0111	CbGpPWpGaD
Salbutamol—ADRB2—G alpha (s) signalling events—PDE4D—esophageal cancer	0.000782	0.0109	CbGpPWpGaD
Salbutamol—ADRB1—Endothelin Pathways—NOS3—esophageal cancer	0.000768	0.0107	CbGpPWpGaD
Salbutamol—ADRB1—G alpha (s) signalling events—GNG7—esophageal cancer	0.000761	0.0106	CbGpPWpGaD
Salbutamol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000756	0.0105	CbGpPWpGaD
Salbutamol—ADRB2—G alpha (s) signalling events—GNG7—esophageal cancer	0.000744	0.0104	CbGpPWpGaD
Salbutamol—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.000716	0.00999	CbGpPWpGaD
Salbutamol—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.000698	0.00974	CbGpPWpGaD
Salbutamol—ADRB1—Calcium Regulation in the Cardiac Cell—GNG7—esophageal cancer	0.000657	0.00916	CbGpPWpGaD
Salbutamol—ADRB1—Calcium Regulation in the Cardiac Cell—SFN—esophageal cancer	0.000652	0.00909	CbGpPWpGaD
Salbutamol—ADRB2—Calcium Regulation in the Cardiac Cell—GNG7—esophageal cancer	0.000642	0.00896	CbGpPWpGaD
Salbutamol—ADRB2—Calcium Regulation in the Cardiac Cell—SFN—esophageal cancer	0.000637	0.00889	CbGpPWpGaD
Salbutamol—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000634	0.00885	CbGpPWpGaD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000538	0.00751	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000535	0.00747	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000531	0.00741	CbGpPWpGaD
Salbutamol—ADRB1—Calcium Regulation in the Cardiac Cell—CALR—esophageal cancer	0.000519	0.00724	CbGpPWpGaD
Salbutamol—ADRB2—Calcium Regulation in the Cardiac Cell—CALR—esophageal cancer	0.000507	0.00708	CbGpPWpGaD
Salbutamol—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.000505	0.00704	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.000493	0.00687	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—ADCYAP1—esophageal cancer	0.000482	0.00672	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000469	0.00655	CbGpPWpGaD
Salbutamol—ADRB2—Arf6 signaling events—EGFR—esophageal cancer	0.000464	0.00648	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000436	0.00609	CbGpPWpGaD
Salbutamol—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000421	0.00587	CbGpPWpGaD
Salbutamol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000401	0.0056	CbGpPWpGaD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000384	0.00535	CbGpPWpGaD
Salbutamol—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000382	0.00534	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000379	0.00528	CbGpPWpGaD
Salbutamol—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00036	0.00502	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000331	0.00461	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000319	0.00446	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000313	0.00436	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000311	0.00434	CbGpPWpGaD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000309	0.00431	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000305	0.00426	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000297	0.00414	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000295	0.00411	CbGpPWpGaD
Salbutamol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000291	0.00406	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000291	0.00405	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000289	0.00403	CbGpPWpGaD
Salbutamol—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000287	0.004	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000284	0.00397	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000283	0.00394	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000282	0.00393	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000278	0.00388	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—GNG7—esophageal cancer	0.000276	0.00385	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000275	0.00384	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000272	0.0038	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—GNG7—esophageal cancer	0.00027	0.00377	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000253	0.00353	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000251	0.0035	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000249	0.00348	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000247	0.00345	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CXCL2—esophageal cancer	0.000243	0.00339	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CXCL2—esophageal cancer	0.000238	0.00332	CbGpPWpGaD
Salbutamol—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000236	0.00329	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000232	0.00323	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GDI2—esophageal cancer	0.000232	0.00323	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000229	0.00319	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GDI2—esophageal cancer	0.000227	0.00316	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—ANXA1—esophageal cancer	0.000226	0.00316	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—ANXA1—esophageal cancer	0.000221	0.00309	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—SST—esophageal cancer	0.00022	0.00307	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000216	0.00301	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—SST—esophageal cancer	0.000215	0.003	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—GHRL—esophageal cancer	0.000214	0.00299	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000213	0.00297	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—GHRL—esophageal cancer	0.00021	0.00293	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKAP13—esophageal cancer	0.000179	0.0025	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000176	0.00245	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKAP13—esophageal cancer	0.000175	0.00245	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KMT2D—esophageal cancer	0.000168	0.00234	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000167	0.00233	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000165	0.0023	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000164	0.00229	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KMT2D—esophageal cancer	0.000164	0.00229	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKAP13—esophageal cancer	0.000163	0.00227	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PDE4D—esophageal cancer	0.00016	0.00224	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKAP13—esophageal cancer	0.000159	0.00222	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000157	0.00218	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GNG7—esophageal cancer	0.000156	0.00218	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GNG7—esophageal cancer	0.000153	0.00213	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000149	0.00208	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PDE4D—esophageal cancer	0.000149	0.00208	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADCYAP1—esophageal cancer	0.000146	0.00204	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PDE4D—esophageal cancer	0.000146	0.00203	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GNG7—esophageal cancer	0.000142	0.00198	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GNG7—esophageal cancer	0.000139	0.00193	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000137	0.00192	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—WWOX—esophageal cancer	0.000137	0.00191	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CXCL2—esophageal cancer	0.000134	0.00188	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—WWOX—esophageal cancer	0.000134	0.00186	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000133	0.00186	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000131	0.00183	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FKBP1A—esophageal cancer	0.00013	0.00181	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000128	0.00178	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FKBP1A—esophageal cancer	0.000127	0.00177	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—WIF1—esophageal cancer	0.000127	0.00177	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000125	0.00175	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—ANXA1—esophageal cancer	0.000125	0.00174	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CXCL2—esophageal cancer	0.000125	0.00174	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—SST—esophageal cancer	0.000124	0.00173	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—WIF1—esophageal cancer	0.000124	0.00173	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000123	0.00172	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCL2—esophageal cancer	0.000122	0.0017	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—SST—esophageal cancer	0.000122	0.0017	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—GHRL—esophageal cancer	0.000121	0.00169	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—GHRL—esophageal cancer	0.000119	0.00165	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000117	0.00163	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—ANXA1—esophageal cancer	0.000116	0.00162	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000115	0.0016	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—ANXA1—esophageal cancer	0.000114	0.00158	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—SST—esophageal cancer	0.000113	0.00158	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—SST—esophageal cancer	0.00011	0.00154	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—GHRL—esophageal cancer	0.00011	0.00154	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PFN1—esophageal cancer	0.00011	0.00153	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—GHRL—esophageal cancer	0.000108	0.0015	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PFN1—esophageal cancer	0.000107	0.0015	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ELMO1—esophageal cancer	9.85e-05	0.00137	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ELMO1—esophageal cancer	9.63e-05	0.00134	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKAP13—esophageal cancer	9.62e-05	0.00134	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKAP13—esophageal cancer	9.41e-05	0.00131	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HIST1H2BM—esophageal cancer	8.88e-05	0.00124	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PDE4D—esophageal cancer	8.8e-05	0.00123	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HIST1H2BM—esophageal cancer	8.69e-05	0.00121	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PDE4D—esophageal cancer	8.61e-05	0.0012	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GNG7—esophageal cancer	8.37e-05	0.00117	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GNG7—esophageal cancer	8.19e-05	0.00114	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—XIAP—esophageal cancer	7.84e-05	0.00109	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—XIAP—esophageal cancer	7.67e-05	0.00107	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CTNNA1—esophageal cancer	7.42e-05	0.00103	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL2—esophageal cancer	7.38e-05	0.00103	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CTNNA1—esophageal cancer	7.26e-05	0.00101	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL2—esophageal cancer	7.22e-05	0.00101	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PSME1—esophageal cancer	6.89e-05	0.000961	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PSME2—esophageal cancer	6.89e-05	0.000961	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ANXA1—esophageal cancer	6.86e-05	0.000957	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PSME2—esophageal cancer	6.74e-05	0.00094	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PSME1—esophageal cancer	6.74e-05	0.00094	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—BLVRB—esophageal cancer	6.73e-05	0.000939	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC52A3—esophageal cancer	6.73e-05	0.000939	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ANXA1—esophageal cancer	6.71e-05	0.000936	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SST—esophageal cancer	6.67e-05	0.000931	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SST—esophageal cancer	6.53e-05	0.00091	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH3—esophageal cancer	6.5e-05	0.000907	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GHRL—esophageal cancer	6.5e-05	0.000907	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FBXW7—esophageal cancer	6.4e-05	0.000892	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH3—esophageal cancer	6.36e-05	0.000887	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GHRL—esophageal cancer	6.36e-05	0.000887	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FBXW7—esophageal cancer	6.26e-05	0.000873	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH2—esophageal cancer	5.83e-05	0.000813	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CA1—esophageal cancer	5.72e-05	0.000798	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SLC10A2—esophageal cancer	5.72e-05	0.000798	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	5.7e-05	0.000796	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CA2—esophageal cancer	5.23e-05	0.00073	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	5.17e-05	0.000722	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	5.06e-05	0.000706	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	4.9e-05	0.000683	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADH7—esophageal cancer	4.86e-05	0.000679	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLCE1—esophageal cancer	4.86e-05	0.000679	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	4.79e-05	0.000668	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADH1B—esophageal cancer	4.26e-05	0.000595	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TYMP—esophageal cancer	4.08e-05	0.000569	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	4.01e-05	0.000559	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.96e-05	0.000553	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	3.92e-05	0.000547	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.86e-05	0.000539	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KDR—esophageal cancer	3.83e-05	0.000534	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KDR—esophageal cancer	3.75e-05	0.000523	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TPI1—esophageal cancer	3.69e-05	0.000514	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTO1—esophageal cancer	3.69e-05	0.000514	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	3.61e-05	0.000503	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.53e-05	0.000493	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	3.53e-05	0.000493	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GAPDH—esophageal cancer	3.4e-05	0.000475	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CRABP1—esophageal cancer	3.37e-05	0.00047	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	3.27e-05	0.000456	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	3.22e-05	0.000449	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GNG7—esophageal cancer	3.21e-05	0.000447	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	3.2e-05	0.000447	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	3.15e-05	0.000439	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	3.07e-05	0.000429	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	3.01e-05	0.000419	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALDH2—esophageal cancer	3e-05	0.000419	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOS3—esophageal cancer	2.93e-05	0.000409	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	2.87e-05	0.0004	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.86e-05	0.000399	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.83e-05	0.000394	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	2.79e-05	0.000389	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	2.74e-05	0.000382	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	2.73e-05	0.000381	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	2.68e-05	0.000374	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.68e-05	0.000374	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ENO1—esophageal cancer	2.68e-05	0.000374	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PSME2—esophageal cancer	2.64e-05	0.000368	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PSME1—esophageal cancer	2.64e-05	0.000368	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCND1—esophageal cancer	2.42e-05	0.000338	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	2.37e-05	0.00033	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	2.34e-05	0.000327	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	2.29e-05	0.00032	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.28e-05	0.000318	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EP300—esophageal cancer	2.23e-05	0.000311	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EP300—esophageal cancer	2.18e-05	0.000304	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP19A1—esophageal cancer	2.14e-05	0.000299	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.95e-05	0.000273	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MYC—esophageal cancer	1.94e-05	0.000271	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MYC—esophageal cancer	1.9e-05	0.000265	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGFR—esophageal cancer	1.9e-05	0.000265	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.88e-05	0.000262	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	1.86e-05	0.000259	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	1.65e-05	0.00023	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	1.61e-05	0.000225	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TP53—esophageal cancer	1.59e-05	0.000222	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TP53—esophageal cancer	1.56e-05	0.000218	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.25e-05	0.000175	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NOS3—esophageal cancer	1.12e-05	0.000157	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.03e-05	0.000143	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—EP300—esophageal cancer	8.54e-06	0.000119	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CA—esophageal cancer	6.31e-06	8.81e-05	CbGpPWpGaD
